KalVista Pharmaceuticals, Inc. (KALV)
NASDAQ: KALV · Real-Time Price · USD
16.46
-0.14 (-0.84%)
At close: Mar 24, 2026, 4:00 PM EDT
16.46
0.00 (0.00%)
After-hours: Mar 24, 2026, 5:46 PM EDT
KalVista Pharmaceuticals Revenue
KalVista Pharmaceuticals had revenue of $13.69M in the quarter ending September 30, 2025.
Revenue (ttm)
$1.43M
Revenue Growth
n/a
P/S Ratio
583.44
Revenue / Employee
$5,281
Employees
270
Market Cap
831.99M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Apr 30, 2025 | - | - | - |
| Apr 30, 2024 | - | - | - |
| Apr 30, 2023 | - | - | - |
| Apr 30, 2022 | - | - | - |
| Apr 30, 2021 | - | - | - |
| Apr 30, 2020 | 12.69M | -3.44M | -21.31% |
| Apr 30, 2019 | 16.13M | 7.73M | 92.13% |
| Apr 30, 2018 | 8.39M | 6.89M | 458.11% |
| Apr 30, 2017 | 1.50M | -629.00K | -29.49% |
| Apr 30, 2016 | 2.13M | 2.10M | 7,255.17% |
| Dec 31, 2015 | 29.00K | - | - |
| Dec 31, 2014 | 29.00K | -386.00K | -93.01% |
| Dec 31, 2013 | 415.00K | -1.12M | -73.02% |
| Dec 31, 2012 | 1.54M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Phathom Pharmaceuticals | 175.11M |
| Xencor | 125.58M |
| UroGen Pharma | 109.79M |
| Inventiva | 19.93M |
| Arbutus Biopharma | 14.08M |
| Evommune | 13.00M |
| Janux Therapeutics | 10.00M |
| Adlai Nortye | -1.35M |
KALV News
- 4 days ago - KalVista Pharmaceuticals to Present New EKTERLY® (sebetralstat) Data at the 2026 Global Angioedema Leadership Conference - Business Wire
- 6 days ago - KalVista Pharmaceuticals to Report Eight Months Fiscal Year 2025 Financial Results and Provide Corporate Update on March 25, 2026 - Business Wire
- 20 days ago - KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 22 days ago - KalVista Pharmaceuticals Presents New Data Highlighting High Patient Satisfaction and Evolving Treatment Trends with EKTERLY® (sebetralstat) - Business Wire
- 27 days ago - KalVista Pharmaceuticals to Present at Upcoming Investor Conferences - Business Wire
- 4 weeks ago - KalVista Pharmaceuticals Announces Inclusion of EKTERLY® (sebetralstat) as a First-Line Therapy for Adolescents 12 and Older in International Pediatric HAE Guideline - Business Wire
- 5 weeks ago - KalVista Pharmaceuticals to Present EKTERLY® (sebetralstat) Data at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting - Business Wire
- 5 weeks ago - KalVista: Next Stage Of Growth For EKTERLY Lies With Pediatric Label Expansion - Seeking Alpha